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Non-immunologic intervention in chronic allograft nephro-
pathy.
Background. Chronic allograft nephropathy is the main cause
of late graft loss. It has been suggested that both alloantigen-
dependent and alloantigen-independent factors influence the
development of progressive transplant failure. The present
study analyzed the importance of non-immunologic factors in
the progression of kidney disease in transplant patients, with
the emphasis on well-established risk factors for progression in
native kidneys.
Methods. A retrospective analysis was performed on 485
renal transplant patients who had functioning kidneys for at
least 1 year. We investigated whether the initial presence and
subsequent maintenance of proteinuria, hypertension, anemia,
hyperlipidemia, and hyperparathyroidism influenced the pro-
gression of transplant failure. To analyze the relative effects of
these factors, patients were categorized into two groups: group
A had a baseline serum creatinine concentration of less than
1.5 mg/dL, and group B had a baseline serum creatinine con-
centration of 1.5 to 3 mg/dL.
Results. High urine protein excretion was a significant inde-
pendent risk factor for progression of renal failure (group A:
relative risk, 3.73; 95% confidence interval [CI], 2.24–6.21;
group B: relative risk, 4.01; 95% CI, 2.51–6.39). Hypertension
was also a significant independent risk factor for progression,
but the risk was lower than for proteinuria (group A: relative
risk, 1.2; 95% CI, 1.04–1.75; group B: relative risk, 1.20; 95% CI,
1.02–2.1). Anemia, hyperlipidemia, and hyperparathyroidism
had no influence on the progression of renal failure.
Conclusion. Our results show strong independent relation-
ships between high blood pressure, urine protein excretion, and
the relative risk of chronic progression of renal failure, as de-
scribed for native kidney disease. These factors are potentially
modifiable and are therefore attractive targets for therapeutic
targets.
Renal allograft failure is the most common cause
of end-stage renal disease after the early post-
transplantation period, accounting for 25% to 30% of
patients awaiting renal transplantation. Despite recent
advances in immunosuppressive therapy, improvements
in long-term graft survival have not been commensu-
rate with those observed with 1-year graft survival [1].
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Clearly, there is a need for the development of better and
more specific strategies to prevent or interrupt chronic
attrition of allografts (approximately 2%–3% per year).
In the kidney, chronic allograft nephropathy is char-
acterized histopathologically by widespread obliterative
vasculopathy, glomerulosclerosis, and interstitial fibrosis
with tubular atrophy. Clinically, recipients of renal trans-
plants who develop this condition experience progressive
proteinuria, hypertension, and azotemia [2].
Despite extensive research on chronic allograft dys-
function, the precise mechanisms responsible for its
characteristic pathologic changes remain unclear. It has
been suggested that both alloantigen-dependent and
alloantigen-independent factors influence the develop-
ment of chronic rejection. Immunologic factors include
T- and B-cell recognition of alloantigens, cytomegalovirus
infection, and endothelial cell activation followed by vas-
cular smooth cell proliferation. The best evidence in sup-
port of the role of alloantigen-dependent factors in the
development of chronic allograft dysfunction is the obser-
vation that its incidence increases after episodes of acute
rejection, accompanied by inadequate immunosuppres-
sion and with increased human leukocyte antigen mis-
matching [3, 4].
At present, there is great interest in the roles of antigen-
independent causes of chronic allograft dysfunction. In
studies on etiologic factors involved in late graft loss, non-
immunologic factors have invariability emerged. These
factors seem to be gaining importance, because rejec-
tion is decreasing because of immunosuppressive regi-
mens and because the demand for organs has resulted
in the use of older donors, kidneys with longer ischemic
periods, and non-beating heart donors [5, 6]. Calcineurin
inhibitor nephrotoxicity is an important issue with regard
to the effect of immunosuppression on chronic allograft
nephropathy, as was demonstrated by Nankivell et al [2].
However, little is known about the roles of established
risk factors (e.g., hypertension and proteinuria) or novel
risk factors (e.g., anemia, hyperparathyroidism, and hy-
perlipidemia) in disease progression in native kidneys in
the transplant situation. There are a number of reasons
for this. A causal role for these factors in the progression
of kidney function decline is difficult to establish, because
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Table 1. Evolution of clinical and biochemical parameters in patients with CPRF and patients with SRF during the 5-year period after
transplantation
Time after transplantation Group 1 y 2 y 3 y 4 y 5 y
Serum creatinine mg/dL SRF 1.5 ± 0.3 1.49 ± 0.25 1.52 ± 0.3 1.56 ± 0.4 1.55 ± 0.35
CPRF 1.69 ± 0.2 1.79 ± 0.5 1.97 ± 0.3a 2.12 ± 0.5a 2.74 ± 0.5a
Proteinuria g/day SRF 0.38 ± 0.3 0.31 ± 0.25 0.35 ± 0.5 0.4 ± 0.3 0.46 ± 0.5
CPRF 0.66 ± 1a 0.66 ± 1.3a 1.02 ± 4a 1.28 ± 5.6a 1.9 ± 18a
Systolic blood pressure mm Hg SRF 139 ± 12 138 ± 15 140 ± 13 141 ± 20 140 ± 15
CPRF 139 ± 15 145 ± 20 149 ± 15a 148 ± 20a 153 ± 23a
Diastolic blood pressure mm Hg SRF 82 ± 7 84 ± 3 84 ± 5 84 ± 4 84 ± 5
CPRF 85 ± 3 85 ± 2 85 ± 5 86 ± 3 87 ± 7
Hemoglobin g/dL SRF 14.3 ± 0.3 14.6 ± 0.5 14.5 ± 0.5 14.6 ± 0.5 14.3 ± 0.2
CPRF 14.2 ± 0.5 14.8 ± 0.6 14.6 ± 0.5 13.9 ± 0.3a 13.5 ± 0.3a
Cholesterol mg/dL SRF 235 ± 56 232 ± 60 234 ± 45 234 ± 80 231 ± 56
CPRF 234 ± 46 238 ± 62 241 ± 50 244 ± 56 245 ± 56
Triglycerides mg/dL SRF 155 ± 25 146 ± 50 147 ± 37 142 ± 25 140 ± 36
CPRF 155 ± 30 154 ± 60 167 ± 50a 161 ± 27a 158 ± 25a
Abbreviations are: CPRF, chronic progressive renal failure; SRF, stable renal function.
aP < 0.05 between groups.
the prevalence and severity of these factors increases with
renal insufficiency [7]. The present study analyzed the im-
portance of non-immunologic factors in the progression
of kidney disease in transplant patients. Special emphasis
was placed on well-established risk factors for progres-
sion in native kidneys that could be attractive therapeutic
targets.
METHODS
Recipients (N = 485; 154 women and 331 men; mean
age, 41.9 ± 11.8 years) of cadaver kidneys transplanted
from 1985 to 1998 who had functioning kidneys for at
least 1 year thereafter were included in the study. Data
on systemic blood pressure (systolic and diastolic), re-
nal function (serum creatinine concentration and cre-
atinine clearance), 24-hour urinary protein excretion,
lipid concentrations (cholesterol, triglycerides, and high-
density lipoprotein cholesterol), indices of phosphocal-
cium metabolism [calcium, phosphorus, and parathyroid
hormone (PTH) concentrations], and hematologic pa-
rameters (hemoglobin and hematocrit) were recorded.
Immunologic data, donor age, and gender as well as
duration of ischemia were also recorded. Baseline data
were recorded at 3 months after transplantation. Hy-
pertension was defined as a systolic/diastolic blood pres-
sure greater than 140/90 mm Hg, proteinuria as urinary
protein excretion greater than 0.5 g per 24 hours, ane-
mia as a hemoglobin level less than 11 g/dL, hyper-
lipemia as a total cholesterolemia level greater than
250 mg/dL or triglyceridemia in excess of 200 mg/dL, and
hyperparathyroidism as a plasma PTH level greater than
150 pg/dL. We analyzed whether the initial presence and
subsequent maintenance of these factors influenced the
progression of transplant failure. Kidney disease progres-
sion was defined as an increase in baseline serum creati-
nine concentration during the study period or as kidney
failure.
Statistical analysis of data was performed using SPSS
software (SPSS version 10.0; SPSS, Chicago, IL, USA).
For comparisons of means, the Student t test and analysis
of variance were used. The chi-square test was used for
comparisons of proportions. Kaplan-Meier curves (com-
pared with the log-rank test) were used to calculate graft
and patient survival, and the Cox proportional hazards
model was used to examine the relationship of variables
with survival. Logistic regression analysis was performed
to estimate relative risks (RR) for independent variables.
P values less than 0.05 were considered significant.
RESULTS
Of the patients, 83% had received their first graft and
17% had received second or successive grafts. Native
kidney disease leading to end-stage renal disease was
primarily due to glomerular disease in 36% of cases, in-
terstitial renal disease in 14.4% of cases, vascular disease
in 10% of cases, and polycystic kidney disease in 12.9%
of cases. The mean follow-up period was 6.41 ± 3.6 years.
Of the patients, 63% were hypertensive, 74% had hy-
perlipidemia, and 20% had proteinuria. Chronic progres-
sive renal transplant failure (CPRF) was associated with
the appearance of hypertension, proteinuria, hyperlipi-
demia, and anemia (Table 1). To analyze the relative ef-
fects of these factors, patients were categorized into two
groups: group A had a baseline serum creatinine concen-
tration of less than 1.5 mg/dL, and group B had a baseline
serum creatinine concentration of 1.5 to 3 mg/dL.
Risk factors for transplant CPRF
Proteinuria. As shown in Figure 1, patients with a
high baseline urine protein excretion had a significantly
greater rate of decline of renal function from 1 year after
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Fig. 1. Progression of kidney disease expressed as serum creatinine in patients with good initial renal function (serum creatinine <1.5 mg/dL, left)
and moderate renal insufficiency (serum creatinine 1.5–3 mg/dL, right) compared with those with (discontinuous line) and without (continuous
line) proteinuria. ∗P < 0.01 for serum creatinine. Differences between proteinuria were significant for all points analyzed.
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Fig. 2. Progression of kidney disease expressed as serum creatinine in patients with good initial renal function (serum creatinine <1.5 mg/dL, left)
and moderate renal insufficiency (serum creatinine 1.5–3 mg/dL, right) compared with those with (squares) and without (triangles) hypertension.
∗P < 0.01 for serum creatinine.
transplantation onwards. This relationship was observed
in both groups. Systolic and diastolic blood pressure did
not differ between groups. High urine protein excretion
was a significant independent risk factor for progression
of renal failure (group A: RR, 3.73; 95% confidence inter-
val [CI], 2.24–6.21; group B: RR, 4.01; 95% CI, 2.51–6.39).
Hypertension. As shown in Figure 2, hypertensive
patients had a significantly faster progression of kidney
disease, especially from 3 years after transplantation on-
wards. This relationship was observed in both groups. Hy-
pertension was a significant independent risk factor for
progression (group A: RR, 1.2; 95% CI, 1.04–1.75; group
B: RR, 1.20; 95% CI, 1.02–2.1), but the risk was lower
than that for proteinuria.
Cholesterol and triglycerides. There was no difference
in concentrations of cholesterol or triglycerides between
patients with or without hyperlipidemia, and neither of
these indices was identified as a risk factor for CPRF by
Cox analysis. The decline in renal function, defined as
an increase in serum creatinine levels, was similar for
both groups: 0.15 ± 0.38 mg/dL per year for patients
with hypercholesterolemia and 0.11 ± 0.41 mg/dL per
year for those without hypercholesterolemia (P = NS).
The change in hypertriglyceridemia was similar for both
groups.
Anemia. There was no association between the pres-
ence of anemia and CPRF. The increase in serum crea-
tinine concentration was 0.12 ± 0.23 mg/dL per year for
patients with anemia and 0.15 ± 0.25 mg/dL per year for
those without anemia (P = NS).
Hyperparathyroidism. In the patients with hyper-
parathyroidism, we observed a significant progression
of transplant failure compared with patients without
hyperparathyroidism from year 3 after transplanta-
tion onwards. However, the association between hyper-
parathyroidism and progression of transplant failure was
not significant in a multivariate survival analysis (RR:
1.38, 95% CI: 0.35–5.34, P = NS).
DISCUSSION
The current study addressed the role of established and
novel non-immunologic risk factors for end-stage native
kidney failure in the progression of chronic renal trans-
plant failure. This study did not analyze other established
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immunologic risk factors (acute rejection, human leuko-
cyte antigen mismatches, panel-reactive antibodies pre-
transplant) or other non-immunologic risk factors (donor
age, ischemia time, immunosuppression) related to trans-
plants [3–5]. Hypertension and proteinuria occur in most
patients with chronic kidney disease and are indicators of
fast progression of kidney disease [7]. Our results show in-
dependent, strong relationships between high blood pres-
sure levels, urine protein excretion, and the risk of CPRF,
as described for native kidney disease. The present study
suggests that at least some risk factors for CPRF may not
be directly linked to immune system activity and native
kidney chronic renal failure.
A persistently high level of urine protein excretion,
both at baseline and during follow-up, is an indepen-
dent risk factor for the progression of transplant fail-
ure. Thus, proteinuria should be considered a modifiable
risk factor. Proteinuria may contribute to disease progres-
sion through a number of mechanisms, including direct
mesangial toxicity, tubular overload, toxicity from spe-
cific filtered proteins, and induction of proinflammatory
molecules. The abnormal filtration of proteins across the
glomerular basement membrane will bring them into con-
tact with the mesangium and tubular cells [8]. Numerous
studies have demonstrated a correlation between the de-
gree of proteinuria and the rate of progression of renal
failure, which has led to the hypothesis that proteinuria
may be an independent mediator of progression rather
than simply a marker of glomerular dysfunction [9]. Pro-
teinuria commonly recedes in the early posttransplant
period, and neither its amount nor its duration is of prog-
nostic significance. However, a poor prognosis has been
described in patients with persistent proteinuria in the
later stages of the posttransplant condition. Moreover,
it is strongly correlated with reduced graft function and
survival [10, 11].
Hypertension is common in patients with renal disease
and contributes significantly to cardiovascular morbid-
ity and mortality. Hypertension is an independent risk
factor for end-stage renal disease, particularly in African
Americans, but in many end-stage renal disease patients,
hypertension develops as a result of the intrinsic renal
malady. It is likely that the degree of secondary hyper-
tension per se contributes to progression of renal disease
under these conditions. Thus, the generation of hyper-
tension perpetuates the chronicity of this condition. It is
recognized that lowering blood pressure with antihyper-
tensive treatment slows progressive renal function loss in
native kidneys [12, 13]. It has been difficult to establish
the exact role of hypertension in chronic allograft dys-
function, because elevations in blood pressure frequently
occur as a result of the progressive allograft failure that
characterizes chronic allograft nephropathy. However,
the present study demonstrates that patients with hyper-
tension also have a more rapid progression of transplant
failure. More aggressive control of blood pressure might
prolong allograft survival.
There is abundant evidence to support the recom-
mendation of renin-angiotensin system (RAS) blockade
therapy as the standard of care for strategies aimed at
preserving renal function in chronic renal disease [14, 15].
Nevertheless, despite the well-established antihyperten-
sive effects of these drugs, the use of RAS blockers in
renal transplantation has been limited, because nephrol-
ogists are concerned about the possibility of inducing
renal insufficiency in patients with a single kidney trans-
plant. However, current knowledge about the ability of
these agents to effectively control blood pressure, uri-
nary protein excretion, and posttransplant erythrocytosis
in kidney transplant recipients suggests that it is now time
to apply RAS blockers to the field of renal transplanta-
tion [16]. Recent studies have documented the efficacy of
blocking the RAS for reducing proteinuria and prevent-
ing renal function deterioration in renal transplantation
[17–19]. Early results are promising. However, available
clinical data are limited in terms of the number of pa-
tients enrolled and cannot be considered definitive. The
Allograft Study was designed to provide an answer to this
problem. This Spanish double-blind, randomized, multi-
center, prospective study aims to assess the progression
of chronic allograft nephropathy by comparing patients
receiving losartan or a placebo.
There are data to suggest that dyslipemia plays an im-
portant role in the initiation and progression of chronic
kidney disease and that the reduction of lipid levels
or modulation of dyslipemia may preserve renal func-
tion or attenuate the progression of renal disease [20].
Few investigations have been conducted to examine
the relationship between lipids and chronic rejection.
We did not observe that lipid abnormalities influenced
CPRF, although the progressive loss of renal function
was accompanied by hyperlipemia. However, because
the pathogenesis of transplant glomerulopathy may share
many features with that of systemic atherosclerosis, it is
logical to hypothesize that lipoprotein abnormalities may
contribute to allograft vasculopathy. The impact of the
pleiotropic effects of statins deserves extensive investi-
gation to determine the clinical relevance of these drugs
in patients with renal disease [21]. In an experimental
model, atorvastatin ameliorated renal lesions through the
diminution of lipids and its lipid-independent pleiotropic
effect [22]. Ji et al demonstrated that pravastatin inhibits
transplant vasculopathy in rat renal allografts [23]. Hy-
pertriglyceridemia at 3 months after transplantation was
associated with decreased graft survival, but treatment
with statins had a protective effect on graft survival in a
study conducted by the Spanish Group for the Study of
Chronic Allograft Nephropathy [24]. However, the As-
sessment of Lescol in Renal Transplantation study estab-
lished the safety and benefits of fluvastatin treatment for
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the prevention of cardiac mortality and for mortality in
renal transplant patients, but not for the preservation of
renal function. The Assessment of Lescol in Renal Trans-
plantation study revealed that serum creatinine levels,
proteinuria, and pulse pressure at baseline were inde-
pendent risk factors for renal outcomes [25].
Secondary hyperparathyroidism is a common compli-
cation of chronic kidney disease. Soft tissue and vascular
calcification, cardiovascular disease, and calcific uremic
arteriolopathy are serious consequences of the disorder
and may contribute directly to cardiovascular morbid-
ity and mortality [26]. Secondary hyperparathyroidism
becomes more pronounced as kidney function declines,
but its relationship with a rapid loss of renal function is
unknown. A number of changes in cardiovascular struc-
ture and function are commonly observed in patients with
chronic renal failure as a result of elevated circulating
parathyroid hormone (PTH). Although acute exposure
to PTH in animals produces hypotension, chronic expo-
sure in animals and humans increases blood pressure. It
has been hypothesized that the mechanism by which PTH
leads to hypertension is associated with the accumula-
tion of calcium in vascular smooth muscle cells. A recent
publication from Ogata et al found that the calcimimetic
NPS R-568 lowered blood pressure and reduced the rate
of progression of chronic renal failure, although it was
not clear whether this beneficial effect was related to
the effect of the drug on lowering intracellular calcium,
the effect on blood pressure, or both [27]. In addition,
several studies suggest that elevated PTH levels in renal
failure patients may contribute to hyperlipemia [26]. We
detected a rapid decline of renal function in patients with
high levels of PTH, but this trend was without statisti-
cal significance, probably because of the small number of
patients from whom PTH was recorded.
Recent studies have reported a prevalence of anemia
of about 30% in renal transplant patients [28]. There is
now evidence suggesting that, as in patients with chronic
renal failure, anemia may negatively affect the long-
term outcomes of kidney transplant recipients [29]. No
studies have evaluated the role of anemia in the pro-
gression of renal dysfunction in kidney transplants. The
REENAL study has clearly shown a correlation between
hemoglobin levels and the rate of progression of type 2
diabetic nephropathy [30]. Chronic anemia limits oxygen
delivery to tissues, and hypoxia is known to be involved
in the regulation of the production of reactive oxygen
species. Both hypoxia and reactive oxygen species stim-
ulate the synthesis of extracellular matrix proteins by
fibroblastic cells and promote the release of proinflam-
matory molecules, leading to interstitial fibrosis that can
contribute to the progression of renal failure, even in re-
nal transplant patients [31]. The role of recombinant hu-
man erythropoietin in renal allograft patients is less clear.
One retrospective study suggests that correcting anemia
may retard progression in chronic renal transplant dys-
function [32]. Our results did not show that anemia had
an influence on the progression of transplant failure.
CONCLUSION
Our study shows that lowering blood pressure and
urine protein excretion could be independent therapeu-
tic goals in the management of transplant glomerulopa-
thy. In addition, novel risk factors for disease progression
in native kidneys such as dyslipidemia, hyperparathy-
roidism, or anemia may be applicable to the transplant
condition. These factors are potentially modifiable and
are therefore attractive therapeutic targets. Antiprotein-
uric and antihypertensive treatment with angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers can further slow the progression of chronic al-
lograft nephropathy.
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